ArticleBiochemistry2026
Three Distinct Binding Modes Govern High-Affinity Ligand Interactions with Amyloid Fibrils.
Article in Biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Fibrillar protein aggregates are a defining feature of neurodegenerative diseases and represent attractive biomarkers and therapeutic targets. However, the rational design of small-molecule ligands and probes targeting these aggregates is limited by a poor understanding of how ligands bind to amyloid fibrils. This work outlines an experimental approach to determine the binding mode of ligands to amyloid fibrils using previously overlooked information contained within standard binding assays. Using a mathematical framework to analyze binding behavior, three distinct high-affinity binding modes were identified: discrete, overlapping, and interacting binding. Reanalysis of published binding data indicates that these binding modes are widespread among common amyloid-binding ligand scaffolds. Two ligands were designed using principles informed by these binding modes, yielding improved binding affinities and characteristic fluorescence responses. These findings establish a practical framework for determining how small molecules bind amyloid fibrils using straightforward binding assays and for guiding the design of future fibril-binding ligands and probes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.